SV Health Investors’s Sutro Biopharma STRO Stock Holding History

SV Health Investors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-182,454	Closed	-$27.1M	–	6
2021 Q4	$27.1M	Hold	182,454	–	–	17.55%	3
2021 Q3	$34.5M	Hold	182,454	–	–	16.87%	4
2021 Q2	$33.9M	Hold	182,454	–	–	14.78%	4
2021 Q1	$41.5M	Hold	182,454	–	–	15.56%	3
2020 Q4	$39.6M	Hold	182,454	–	–	19.08%	2
2020 Q3	$18.3M	Hold	182,454	–	–	9.29%	6
2020 Q2	$14.2M	Hold	182,454	–	–	9.82%	6
2020 Q1	$18.6M	Hold	182,454	–	–	15.61%	3
2019 Q4	$20.1M	Hold	182,454	–	–	12.16%	5
2019 Q3	$16.6M	Hold	182,454	–	–	11.65%	6
2019 Q2	$20.8M	Hold	182,454	–	–	13.94%	3
2019 Q1	$20.8M	Hold	182,454	–	–	12.19%	4
2018 Q4	$16.5M	Hold	182,454	–	–	10.13%	4
2018 Q3	$27.4M	Buy	+182,454	New	+$27.6M	8.01%	5

Other funds holding STRO

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

SV Health Investors's STRO Position: Q1 2022 in Review

SV Health Investors sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 182,454 shares — an estimated $27.1M sold.

SV Health Investors first reported a position in STRO in Q3 2018 and held it in 14 quarters. The position peaked at $41.5M in Q1 2021. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

SV Health Investors reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
SV Health Investors sold 182,454 Sutro Biopharma shares in Q1 2022, an estimated $27.1M.
SV Health Investors first reported a position in Sutro Biopharma in Q3 2018 and held it in 14 quarters.
SV Health Investors's Sutro Biopharma position peaked at $41.5M in Q1 2021.
115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on SV Health Investors's 13F filing for Q1 2022, filed 16 May 2022.